About Me
Conditions and Treatments
Conditions
- astigmatism
- blepharitis
- cataract
- conjunctivitis
- corneal disease
- dry eye syndrome
- eye floater
- eye redness
- glaucoma
- hyperopia
- myopia
- ocular herpes
- presbyopia
- refractive error
- stye
- uveitis
Treatments
- eye surgery
Learn more about conditions we treat at NYU Langone:
Cataract , Conjunctivitis , Dry Eye Syndrome , Glaucoma , Refractive Error , StyeCredentials
Positions
- Clinical Assistant Professor, Department of Ophthalmology at NYU Grossman School of Medicine
Board Certifications
- American Board of Ophthalmology - Ophthalmology, 2013
Education and Training
- Residency, NYU Grossman School of Medicine, Ophthalmology, 2012
- MD from Northwestern University, 2008
Is this your profile?
Edit profileInsurance Plans Accepted
This provider accepts the following insurance plans.
-
Aetna
- Aetna HMO
- Aetna Indemnity
- Aetna Medicare
- Aetna POS
- Aetna PPO/EPO
-
Blue Cross Blue Shield
- Empire BCBS Top Tier
-
Cigna
- Cigna EPO/POS
- Cigna Medicare
- Cigna PPO
-
Empire Blue Cross Blue Shield
- Empire Blue Cross Blue Shield EPO
- Empire Blue Cross Blue Shield HMO
- Empire Blue Cross Blue Shield Indemnity
- Empire Blue Cross Blue Shield MediBlue
- Empire Blue Cross Blue Shield POS
- Empire Blue Cross Blue Shield PPO
- Empire Blue Cross Blue Shield Pathways, Enhanced
-
HIP
- HIP Access I
- HIP Access II
- HIP Child Health
- HIP EPO/PPO
- HIP HMO
- HIP Medicare
- HIP POS
-
Local 1199
- Local 1199 PPO
-
MagnaCare
- MagnaCare PPO
-
MultiPlan/PHCS
- MultiPlan/PHCS PPO
-
NYS Health Insurance Plan
- The Empire Plan
-
Oxford
- Oxford Freedom
- Oxford Liberty
- Oxford Medicare
-
UHC
- UnitedHealthcare EPO
- UnitedHealthcare HMO
- UnitedHealthcare Medicare
- UnitedHealthcare POS
- UnitedHealthcare PPO
- UnitedHealthcare Top Tier
Jonathan B. Kahn, MD does not accept insurance.
Locations and Appointments
Madison Ophthalmology PLLC
161 Madison Avenue, Ste 5SE, New York, NY 10016
Research Academic Contact
Academic office
161 Madison Avenue, Suite 5-SE
New York, NY 10016
Phone
212-448-0101
Fax
212-448-0116
Clinical Trials and Research Studies
-
Nivolumab will be investigated at the Food and Drug Administration (FDA)-approved dose of 480 mg intravenous (IV) every 4 weeks until unacceptable toxicity disease progression or completion of 2 years of therapy. If that dose and schedule have unaccepta
-
The proposed first-in-human study of XMT-2056 will be a Phase 1 open-label study of XMT-2056 in previously treated patients with advanced/recurrent solid tumors expressing HER2. The XMT-2056 monotherapy trial will consist of dose escalation (DES) and exp
-
Study 849-001 is a multi-center Phase 1/2 multiple expansion cohort trial evaluating the safety PK metabolites PD and clinical activity/efficacy of MRTX849 in patients with advanced solid tumor malignancies with KRAS G12C mutation. This protocol is d
Publications
-
Gad, Rania E.; Kahn, Jonathan; Trief, Danielle
Case reports in ophthalmology. 2024 Jan 01; 41-46
-
Tauber, Jenna; Chinwuba, Ijeoma; Kleyn, David; Rothschild, Michael; Kahn, Jonathan; Thiel, Cassandra L
JAMA ophthalmology. 2019 Oct 01; 137(10):1156-1163
-
Van Pilsum Rasmussen, S E; Henderson, M L; Kahn, J; Segev, D L
American journal of transplantation. 2017 Oct ; 17(10):2567-2571